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Figure 1. Trajectory of MS
Figure1. Relapse onset MS leads to the progressive accumulation of disability after 10-15 years with fewer




































Number of approved DMTs
Figure 2. Armamentarium of disease-modifying therapies (DMTs) 2016
Approved DMTs in 2016;  β-interferon-1a(Avonex), β-interferon-1b(betaferon), Glatiramer Acetate (Copaxone), 
Mitoxantrone (Novantrone)*, β-interferon-1a(Rebif), Natalizumab (Tysabri), Teriflunomide (Aubagio), 
Alemtuzumab (Lemtrada), Fingolimod (Gilenya), Dimethyl fumarate (Tecfidera),Interferon beta 1b (Extavia), β-
interferon-1a (Plegridy).
This is a line graph of MS disease-modifying therapies (DMTs) which have European Medicines Agency (EMA) or
Food and Drug Administration (FDA) approval. The vertical axis is the number of approved disease modifying
therapies. The horizontal axis is year of approval. *Mitoxantrone (Novantrone) has FDA approval only.
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Table 3. UK-licensed disease-modifying treatments (DMTs) for Relapsing Remitting MS
Glossary: RRMS (Relapsing Remitting Multiple Sclerosis), EDSS (Expanded Disability Status Scale), CIS (Clinically
Isolated Syndrome), SPMS ( Secondary Progressive Multiple Sclerosis), IPIR (immediate post-injection
reaction), RES (Rapidly evolving severe), PML (Progressive Multifocal Leucoencephalopathy), ABN(Association
of British Neurologists).
Comment: NHS England has taken on commisioning of the drugs since 2013 and advices that patients must be
under the care of a designated MS centre which is registered to take part in the national risk sharing scheme
involving the three beta interferon products and glatiramer acetate. The Association of British Neurologists
(ABN) advices an annual review whilst on DMTs that will need to be conducted by the MS specialist
neurologist who is also best placed to determine whether MRI scanning is required.
Sources:
1. Scolding N, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-
modifying treatments in multiple sclerosis. Practical Neurology 2015;15(4):273-279.
2. Multiple Sclerosis Trust. Disease Modifying Drugs. Multiple Sclerosis Trust Publication ID 90. November
2015.
3. National Institute for Clinical Excellence (NICE) Clinical Guidelines CG186. Multiple sclerosis in adults:
management. October 2014.
4. National Health Service (NHS) England. Clinical commissioning policy: disease modifying therapies for
patients with multiple sclerosis (MS) May 2014 NHS England/ D04/P/b
5. https://www.medicinescomplete.com/mc/martindale
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Table 4. Suggested symptomatic treatments in MS
